Welcome to our dedicated page for Opko Health news (Ticker: $OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Opko Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Opko Health's position in the market.
OPKO Health, Inc. (NASDAQ: OPK) reported first quarter 2024 business highlights and financial results. Highlights include an agreement with Labcorp to sell select assets of BioReference Health for $237.5 million, as well as FDA clearance for MDX2001, a tetraspecific antibody for solid tumor cancers. The global launch of NGENLA® by Pfizer is ongoing, with OPKO entitled to profit sharing and potential milestone payments. Financially, revenue declined to $173.7 million from $237.6 million in 2023, resulting in an operating loss of $71.5 million for Q1 2024.
OPKO Health, Inc. (NASDAQ: OPK) will release its financial results for the first quarter of 2024 on May 7, 2024. The company's senior management will discuss the results and provide financial guidance during a conference call and webcast.